Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort
Rheumatology International · 2025
DOI: 10.1007/s00296-025-05941-0 ↗At a glance
Journal article in Rheumatology International, 2025. Written by Yuki Imai and 2 co-authors. Institution: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan. Major MEDLINE topics: Polymyalgia Rheumatica, Antibodies, Monoclonal, Humanized, Glucocorticoids, Immunosuppressive Agents. 42 references.
Abstract (original language)
OBJECTIVE: This study aimed to evaluate the effectiveness and safety of tocilizumab in polymyalgia rheumatica (PMR) in the real world. METHODS: All consecutive patients diagnosed with PMR who visited Keio University Hospital between May 2012 and October 2022 were retrospectively reviewed. Patients were divided into three groups: the tocilizumab group, the immunosuppressant group without biological agents, and the glucocorticoid monotherapy group. We collected clinical data including relapse, glucocorticoid doses, and adverse events during follow-up. RESULTS: A total of 125 patients with PMR was included in the analyses, with a mean age of 73.6 years and 83 (66.4%) female. Among them, 52 (41.6%) were in the tocilizumab group, 23 (18.4%) in the immunosuppressant group, and 50 (40.0%) in the glucocorticoid group. The glucocorticoid group showed the lowest serum C-reactive protein level at diagnosis (P = 0.046). Tocilizumab extended the time to relapse, even when given to patients with a relatively refractory disease course, although relapse assessment was not independent of C-reactive protein levels. The time to glucocorticoid discontinuation was the shortest in the tocilizumab group (P < 0.001 for induction or re-induction, P = 0.08 for maintenance). Tocilizumab use, methotrexate use and the number of relapses were identified as significant predictors of achieving glucocorticoid-free status. Adverse events were not significantly different between the three groups. CONCLUSION: Tocilizumab effectively reduced relapse rates and demonstrated glucocorticoid-sparing effects in patients with refractory PMR in the real world, with no significant safety issues. These results further support the existing evidence that tocilizumab may be a promising treatment option in real-world settings.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan. ykaneko.z6@keio.jp.
Cite
APA
Imai, Y., Takanashi, S., & Kaneko, Y. (2025). Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort. Rheumatology International. https://doi.org/10.1007/s00296-025-05941-0
Vancouver
Imai Y, Takanashi S, Kaneko Y. Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort. Rheumatology International. 2025. doi:10.1007/s00296-025-05941-0
BibTeX
@article{Imai2025,
author = {Imai, Yuki and Takanashi, Satoshi and Kaneko, Yuko},
title = {Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort},
journal = {Rheumatology International},
year = {2025},
doi = {10.1007/s00296-025-05941-0}
}
EUVIMED